( MENAFN - GlobeNewsWire - Nasdaq) Results show combination of OCA 5-10 mg and bezafibrate 400 mg normalizes multiple serum biomarkers that are associated with improved transplant-free and decompensation-free survival in PBC MORRISTOWN, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
, a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A.
focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced new data from a planned six-month analysis of its ongoing Phase 2 study 747-213 evaluating the combination of obeticholic acid (OCA) and bezafibrate in patients with primary biliary cholangitis (PBC) at the European Association for the Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024, in Milan, Italy. Results from the study show that six-month administration of OCA and bezafibrate has the potential to normalize multiple serum biomarkers associated with improved transplant-free and decompensation-free survival in PBC. “These data add to a growing body of evidence showing that the combination of OCA and bezafibrate may provide additive clinical efficacy and tolerability benefits in the treatment of PBC,” said David Jones, Professor of Liver Immunology, Newcastle University.
“This investigational, combination therapy is the first we've seen to induce biochemical remission – or normalization of multiple biomarkers – in the majority of patients, mark.
